Sandoz Shares Rise Following $322 Million Biosimilar Deal With Henlius
Sandoz shares advanced after the company announced a biosimilar agreement valued at $322 million with Henlius.
PA
Priya Anand · Equities & Earnings Desk · 17 Aug 2026 · 1 min read
Sandoz shares increased following the announcement of a $322 million biosimilar agreement with Henlius.
Financial terms of the transaction value the partnership at $322 million, focusing on the development and commercialization of biosimilar products. Further details regarding the specific pipeline assets involved and the timeline for regulatory filings were not immediately disclosed.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →